Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report
RET-rearranged non-small cell lung cancer (NSCLC) is a rare molecular subtype, accounting for 1-2% of all lung cancers. Selpercatinib, a selective RET tyrosine kinase inhibitor (TKI), has demonstrated efficacy in this oncogene-addicted population, but data on rechallenge after disease progression are lacking.